PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

If you know what a TAVR procedure is; a shiny gold star for you. And if you know why, at Overlake Medical Center, they call the second day of the work week “TAVR Tuesdays,” you get two gold stars. And ...

Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA. At ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

An expert panel has issued an algorithm strategy for managing conduction disturbances associated with transcatheter aortic valve replacement (TAVR). The panel included a multidisciplinary group of ...